Sanofi

Christophe Gaudin

Davide Radzik

Martin Van Eickels

Jens Stechl

Pascale Ythier-Moury

Nacéra Hamdani

Angèle Moryusef

Angele Moryusef

Nacera Hamdani

The invention relates to otamixaban or a pharmaceutically acceptable salt thereof for use in the treatment of non-ST elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting.

Otamixaban for use in the treatment of non-ST elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting

The invention relates to the use of (2R,3R)-2-(3-carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl)benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in non-ST elevation myocardial infarction, said treatment comprising administering a therapeutically effective amount of (2R,3R)-2-(3-Carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl)benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof to a human patient, who is elderly and/or shows renal insufficiency and/or has a low body weight.

Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients

Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.

Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality

Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality

Growing community of inventors

Paris, France

Christophe Gaudin